Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $25.51 million. The enterprise value is $3.21 million.
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024, before market open.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.57% in one year.
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | +1.57% |
| Shares Change (QoQ) | -0.25% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | 10.00% |
| Float | 5.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.28 |
| Forward PS | 19.64 |
| PB Ratio | 1.20 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.56, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.56 |
| Quick Ratio | 12.40 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.12% and return on invested capital (ROIC) is -24.15%.
| Return on Equity (ROE) | -34.12% |
| Return on Assets (ROA) | -22.67% |
| Return on Capital (ROIC) | -24.15% |
| Revenue Per Employee | $282,408 |
| Profits Per Employee | -$499,308 |
| Employee Count | 17 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $1,236 in taxes.
| Income Tax | 1,236 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.07% in the last 52 weeks. The beta is 1.21, so Lipocine's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | +39.07% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 4.86 |
| Relative Strength Index (RSI) | 60.21 |
| Average Volume (20 Days) | 38,984 |
Short Selling Information
The latest short interest is 134,367, so 2.51% of the outstanding shares have been sold short.
| Short Interest | 134,367 |
| Short Previous Month | 141,386 |
| Short % of Shares Out | 2.51% |
| Short % of Float | 2.59% |
| Short Ratio (days to cover) | 4.81 |
Income Statement
In the last 12 months, Lipocine had revenue of $4.80 million and -$8.49 million in losses. Loss per share was -$1.61.
| Revenue | 4.80M |
| Gross Profit | 4.80M |
| Operating Income | -9.71M |
| Pretax Income | -8.49M |
| Net Income | -8.49M |
| EBITDA | -9.67M |
| EBIT | -9.71M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $22.55 million in cash and $245,384 in debt, giving a net cash position of $22.30 million or $4.17 per share.
| Cash & Cash Equivalents | 22.55M |
| Total Debt | 245,384 |
| Net Cash | 22.30M |
| Net Cash Per Share | $4.17 |
| Equity (Book Value) | 21.21M |
| Book Value Per Share | 3.97 |
| Working Capital | 21.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.72 million and capital expenditures -$9,167, giving a free cash flow of -$4.73 million.
| Operating Cash Flow | -4.72M |
| Capital Expenditures | -9,167 |
| Free Cash Flow | -4.73M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -202.18% and -176.80%.
| Gross Margin | 100.00% |
| Operating Margin | -202.18% |
| Pretax Margin | -176.78% |
| Profit Margin | -176.80% |
| EBITDA Margin | -201.50% |
| EBIT Margin | -202.18% |
| FCF Margin | -98.48% |